Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index-Reference-Cited by-同舟云学术

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index

Published:2021-07-29 Issue:10 Volume:23 Page:1662-1672
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Adamson Carly¹,Jhund Pardeep S.¹,Docherty Kieran F.¹,Bělohlávek Jan²,Chiang Chern‐En³⁴,Diez Mirta⁵,Drożdż Jarosław⁶,Dukát Andrej⁷,Howlett Jonathan⁸,Ljungman Charlotta E.A.⁹,Petrie Mark C.¹,Schou Morten¹⁰,Inzucchi Silvio E.¹¹,Køber Lars¹²,Kosiborod Mikhail N.¹³¹⁴,Martinez Felipe A.¹⁵,Ponikowski Piotr¹⁶,Sabatine Marc S.¹⁷,Solomon Scott D.¹⁸,Bengtsson Olof¹⁹,Langkilde Anna Maria¹⁹,Lindholm Daniel¹⁹,Sjöstrand Mikaela¹⁹,McMurray John J.V.¹

Affiliation:

1. BHF Cardiovascular Research Centre University of Glasgow Glasgow UK

2. Second Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital, First Faculty of Medicine Charles University Prague Czech Republic

3. Division of Cardiology Taipei Veterans General Hospital Taipei Taiwan

4. National Yang Ming Chiao Tung University Taipei Taiwan

5. Division of Cardiology Instituto Cardiovascular de Buenos Aires Buenos Aires Argentina

6. Department Cardiology Medical University of Lodz Lodz Poland

7. Fifth Department of Internal Medicine Comenius University in Bratislava Bratislava Slovakia

8. Libin Cardiovascular Institute, Cumming School of Medicine University of Calgary Calgary Canada

9. Institute of Medicine, Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

10. Department of Cardiology Gentofte University Hospital Copenhagen Copenhagen Denmark

11. Section of Endocrinology Yale School of Medicine New Haven CT USA

12. Department of Cardiology Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark

13. Saint Luke's Mid America Heart Institute University of Missouri Kansas City MO USA

14. The George Institute for Global Health University of New South Wales Sydney Australia

15. Universidad Nacional de Córdoba Córdoba Argentina

16. Center for Heart Diseases, University Hospital Wroclaw Medical University Wroclaw Poland

17. TIMI Study Group, Brigham and Women's Hospital Boston MA USA

18. Division of Cardiovascular Medicine Brigham and Women's Hospital Boston MA USA

19. Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2308

Reference36 articles.

1. The Obesity Paradox and Heart Failure: A Systematic Review of a Decade of Evidence

2. Body mass index and mortality in heart failure: A meta-analysis

3. Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis

4. Obesity and the Obesity Paradox in Heart Failure

5. Meta-Analysis of the Relation of Body Mass Index to All-Cause and Cardiovascular Mortality and Hospitalization in Patients With Chronic Heart Failure

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Body Mass Index and Clinical and Health Status Outcomes in Chronic Coronary Disease and Advanced Kidney Disease in the ISCHEMIA-CKD Trial;The American Journal of Medicine;2024-02

2. The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?;Journal of Personalized Medicine;2024-01-26

3. Managing Obesity in Heart Failure;JACC: Heart Failure;2024-01

4. Association between BMI and Efficacy of SGLT2 Inhibitors in Patients with Heart Failure or at Risk of Heart Failure: A Meta-Analysis Based on Randomized Controlled Trials;Cardiology;2023-11-24

5. A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control;2023-11-07